Sanofi plots strategy for India; Amgen declares fourth-quarter dividend;

@FiercePharma: India's pharma industry is the country's 2nd-best at making billionaires. More | Follow @FiercePharma

> Sanofi ($SNY) is weighing its strategy in India, now that it has launched the first locally manufactured insulin pen. Report

> Amgen's ($AMGN) board of directors approved a $0.36-per-share dividend to be paid Dec. 7. Report

> Actavis won FDA approval for its version of the Valeant Pharmaceuticals ($VRX) heart drug Tiazac, which treats high blood pressure. Report

> Canadians may find their favorite over-the-counter cold and flu medications in short supply because of ongoing supply problems at a Novartis ($NVS) plant. Report

> The Canadian pharmacy group Jean Coutu saw profits rise on growth at its generic drugmaker Pro Doc. Report

> Congressional staffers expect FDA Commissioner Margaret Hamburg to remain in her post if President Obama is re-elected. Report

Medical Device News

 @FierceMedDev: As BSX has implied, the job cuts are coming. More | Follow @FierceMedDev

 @MarkHFierce: Not only is angel investing recovering, but much of it seems to be hitting medical device startups. More | Follow @MarkHFierce

 @DamianFierce: Four former Synthes execs have been effectively blacklisted from the life sciences industry. More | Follow @DamianFierce

> J&J's Cordis touts stent for femoral artery disease. Story

> Medical devices drive the start of an angel investor rebound. Item

> Quest Diagnostics slashing 400-600 jobs to save $65M. More

Biotech News

 @FierceBiotech: New special report: Top diabetes drug pipelines of 2012. Feature | Follow @FierceBiotech

 @JohnCFierce: Kythera IPO prices at high end of range (I don't write that very often). More | Follow @JohnCFierce

 @RyanMFierce: GSK will decide whether to grant access to the ID-less patient data based on scientific merit. Sounds subjective, but progress nonetheless. | Follow @RyanMFierce

> Sanofi argues its R&D costs are too high, but backs down on Toulouse. Story

> Will GlaxoSmithKline's transparency pledge force pharma rivals to open up? Article

Pharma Manufacturing News

> Novasep investing in another API expansion. News

> Auctus Pharma API plant in India catches fire. Report

> Merck opens $21M Jakarta packaging plant. Story

Vaccines News

> GSK, Aeras partner for TB vaccine trial. More

> Merck taps Vaxxas for Nanopatch vaccine delivery. Story

> Pfizer's Prevnar 13 posts positive late-stage data. Report

> Takeda snaps up LigoCyte for $60M. Item

And Finally... Wired magazine joined the lobbying for a drug-development prize to replace current patent-system incentives. Report

Suggested Articles

It's taken years for Amarin's Vascepa to prove itself as a game-changing treatment for CV disease. An FDA committee may have just punched its pass.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

With a potential approval next year in the up-and-coming NASH field, Intercept is staffing up its sales team and starting talks with payers.